Cetrorelix
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Cetrorelix: From Ovarian Stimulation Support to Hypertrichosis
One-Sentence Summary
Cetrorelix is a GnRH (gonadotropin-releasing hormone) antagonist used in fertility treatment to prevent premature LH surges during controlled ovarian stimulation. The TxGNN model predicts it may be effective for hypertrichosis, but there are currently 0 clinical trials and 0 publications supporting this direction. This prediction is based on model output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Prevention of premature LH surges in women undergoing controlled ovarian stimulation (the Health Canada licence text is not available; this is based on pharmacology reference data) |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 0.9998 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Based on known pharmacology, cetrorelix blocks the GnRH1 receptor (encoded by GNRHR). This suppresses LH and FSH release and lowers downstream sex-steroid (androgen and estrogen) production.
In theory, lowering androgens could reduce androgen-driven hair growth (hirsutism). However, hypertrichosis is generally not androgen-dependent. It is often genetic or drug-induced, so the mechanistic link is speculative. The very high TxGNN score (0.9998) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Other top-ranked predictions are also poorly supported mechanistically:
- Ambras-type hypertrichosis, isolated hair shaft abnormalities, familial trichomegaly: these are developmental or genetic hair disorders that GnRH antagonism does not address.
- Dental/periodontal malformation syndromes, Dandy-Walker–related syndromes, persistent fetal circulation: no plausible mechanism.
- Familial male-limited precocious puberty, aromatase excess syndrome: related to the sex-hormone axis but mismatched. The pathology lies downstream of the pituitary or outside the gonads.
- Central precocious puberty (rank 10): the most biologically credible prediction. The disease is driven by premature activation of the hypothalamic-pituitary-gonadal axis, and GnRH axis suppression is pharmacologically coherent. The standard of care, however, is GnRH agonists. No trial or literature data were supplied for cetrorelix in children, and its short-acting formulation limits practicality. It is flagged as a research question.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02247766 | CETROTIDE | Not specified | Not specified |
Safety Considerations
- Drug Interactions: No drug-drug interactions were identified. The only record is pharmacological: cetrorelix acts on the human GnRH1 receptor and is used to inhibit premature LH surges in women undergoing controlled ovarian stimulation.
Please refer to the package insert for other safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a computational score, with no clinical trials or literature, and the mechanistic link to hypertrichosis is weak. Package-insert safety data have also not been obtained.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism-of-action data (for example from DrugBank)
- Literature and trial searches for hypertrichosis, and separately for central precocious puberty, the most plausible candidate
- Assessment of route and formulation suitability, including pediatric suitability if central precocious puberty is pursued
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.